Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2019 08:00 ET | Source: Poseida Therapeutics, Inc.

Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma

SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving...
April 22, 2019 07:00 ET | Source: Poseida Therapeutics, Inc.

Poseida Therapeutics Raises $142 Million in Series C Financing

SAN DIEGO, April 22, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create...
February 13, 2019 08:00 ET | Source: Poseida Therapeutics, Inc.

Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks

SAN DIEGO, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create...
January 04, 2019 16:53 ET | Source: Poseida Therapeutics, Inc.

Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions

SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create...
December 03, 2018 21:15 ET | Source: Poseida Therapeutics, Inc.

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create...
November 29, 2018 08:00 ET | Source: Poseida Therapeutics, Inc.

Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting

SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging proprietary next-generation, non-viral gene engineering...
November 05, 2018 08:00 ET | Source: Poseida Therapeutics, Inc.

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101

SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging proprietary next-generation, non-viral gene engineering...
October 09, 2018 08:00 ET | Source: Poseida Therapeutics, Inc.

Poseida Therapeutics Appoints Marcy Graham as Vice President, Corporate Affairs

SAN DIEGO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today...
September 05, 2018 09:15 ET | Source: Poseida Therapeutics, Inc.

Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma

Efficacy and safety continue to be a major advantage, with a very high response rate, no dose limiting toxicities and only a single incidence of suspected cytokine release syndrome P-BCMA-101...
August 29, 2018 05:00 ET | Source: Poseida Therapeutics, Inc.

Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018

SAN DIEGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies,...

Next Page keyboard_arrow_right